• Alvotech recently announced it had finalized a global licensing and settlement agreement with Regeneron and Bayer, resolving past worldwide patent disputes over its Eylea 2mg (aflibercept) biosimilar and setting 2026 launch dates across the UK, Canada, Japan, the European Economic Area and other markets, alongside an earlier U.S. license entry date.
• This settlement removes a key legal overhang and gives Alvotech and its partners clear worldwide rights to manufacture and supply the aflibercept biosimilar, potentially reshaping competition in retinal disease treatments.
• We’ll now examine how securing worldwide commercialization rights and clear launch timelines for the aflibercept biosimilar shapes Alvotech’s investment narrative.

We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Alvotech's Investment Narrative?

For Alvotech, the big-picture belief is that a focused biosimilar specialist can turn a broad, already-approved pipeline into sustained cash generation despite a stretched balance sheet and past execution hiccups. The newly announced global settlement on its Eylea biosimilar fits squarely into that thesis: it removes a major legal unknown and gives the company firm 2026 launch slots across key ophthalmology markets, which now looks like one of the nearer term commercial catalysts in the story. At the same time, it does not erase the other pressure points. The stock is still coming off a sharp 12‑month drawdown, carries a heavy debt load, and faces an FDA setback at its Reykjavik site alongside a high level of non cash earnings. The settlement upgrades visibility on one asset, but it does not simplify everything else.

However, investors should also be aware of Alvotech’s leverage, regulatory overhang and quality of earnings. Alvotech's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Eight members of the Simply Wall St Community currently place Alvotech’s fair value anywhere from US$5.00 to a very large figure above US$2,600, underlining just how far apart individual views can be. Set against the recent Eylea settlement and ongoing concerns around debt servicing and manufacturing compliance, this spread in expectations shows why it can be useful to weigh several perspectives before forming a view on the company’s potential path.

Explore 8 other fair value estimates on Alvotech - why the stock might be worth 7% less than the current price!

Build Your Own Alvotech Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find companies with promising cash flow potential yet trading below their fair value.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.